Skip to main content
SpringerLink
Log in

Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

The objective of this study was to investigate the effects of irbesartan, carvedilol, and irbesartan plus carvedilol on the expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) mRNA and protein in rat myocardium after myocardial infarction (MI). MI was induced in male Wistar rats by ligation of the anterior descending branch of the left coronary artery. Irbesartan at 50 mg/kg/day, carvedilol at 1 mg/kg/day, irbesartan plus carvedilol, or placebo was administered intragastrically; expression of TF and TFPI mRNA and protein was determined by RT-PCR and Western blot analysis. The relative left ventricle weights were lower in all three treatment groups than in the placebo group, with the lowest relative weight in the irbesartan plus carvedilol group (P < 0.001). The size of the infarcted area was lower in the carvedilol and the combined groups than in the placebo group (P < 0.001). The levels of expression of TF and TFPI mRNA and protein were lower in the combined group than in the placebo group or the carvedilol group (P < 0.001). Treatment with irbesartan plus carvedilol reduced the expression of TF and TFPI mRNA and protein after MI in rats, and combined treatment with both agents had greater effects than the single agents alone. These findings suggest that the beneficial effects of these drugs may include anticoagulation and that combined therapy with both agents is an option that should be evaluated further.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N (1997) Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 29:1060–1066

    Article  PubMed  CAS  Google Scholar 

  2. Senior R, Basu S, Kinsey C, Schaeffer S, Lahiri A (1999) Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 137:646–652

    Article  PubMed  CAS  Google Scholar 

  3. Yang YJ, Zhang P, Ruan YM (2000) Comparison of losartan, enalapril and their combination in preventing ventricular remodeling after myocardial infarction in rats. Eur Heart J 21(Suppl):72

    Google Scholar 

  4. Yang YJ, Tang YD, Zhang P, Ruan YM, Xu XL, Zhou YW, Tian Y, Gao RL, Chen JL, Chen ZJ (2001) Effects of different doses of carvedilol for prevention and treatment of left ventricular remodeling in rats with acute myocardial infarction. Chin J Med 81:927–930

    CAS  Google Scholar 

  5. Richer C, Fomes P, Cazaubon C, Domergue V, Nisato D, Giudicelli JF (1999) Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res 41:100–108

    Article  PubMed  CAS  Google Scholar 

  6. Fernandes-Santos C, Mendonca L, Mandarin-de-Lacerda CA (2009) Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats. Heart Vessels 24:219–227

    Article  PubMed  Google Scholar 

  7. Tsuda M, Iwai M, Li J-M, Li H-G, Min L-J, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M (2005) Inhibitory effect of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 45:545–551

    Article  PubMed  CAS  Google Scholar 

  8. Steppich BA, Braun SL, Stein A, Demetz G, Groha P, Schömig A, von Beckerath N, Kastrati A, Ott I (2009) Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. Thromb J 7:11. doi:10.1186/1477-9560-7-11

    Article  PubMed  Google Scholar 

  9. Zaman AG, Helft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251–266

    Article  PubMed  CAS  Google Scholar 

  10. Steppich B, Mattisek C, Sobczyk D, Kastrati A, Schömig A, Ott I (2005) Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. Thromb Haemost 93:35–39

    PubMed  CAS  Google Scholar 

  11. Koh KK, Chung WJ, Ahn JY, Han SH, Kang WC, Seo YH, Ahn TH, Choi IS, Shin EK (2004) Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 177:155–160

    Article  PubMed  CAS  Google Scholar 

  12. Yang QF, Li CL, Chen J, Liu J, Liu H, Hu FC, Hu YC, Zhang YZ (2003) Effects of carvedilol on blood viscosity and platelet aggregation in patients with essential hypertension. Henan Univ Trans Med Sci Ed 22:20–22

    Google Scholar 

  13. Zang RY, Sun YH, Huang YL (2002) Effects of fosinopril, irbesartan and combined treatment on ventricular remodeling after myocardial infarction. Chin J Cardiol 30(10):626–629

    Google Scholar 

  14. Nishiyama M, Park IS, Yoshikawa T, Hatai Y, Ando M, Takahashi Y, Mori K, Murakami Y (2009) Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease. Heart Vessels 24:187–192

    Article  PubMed  Google Scholar 

  15. Schneider MP, Klingbeil AU, Delles C, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE (2004) Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the cardiovascular irbesartan project. Hypertension 44:61–66

    Article  PubMed  CAS  Google Scholar 

  16. Toda N (2003) Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 100:215–234

    Article  PubMed  CAS  Google Scholar 

  17. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N, CAPRICORN Echo Substudy Investigators (2004) Effects of carvedilol on left ventricular remodeling after acute myocardial iinfarction: the CAPRICORN Echo Substudy. Circulation 109:201–206

    Article  PubMed  CAS  Google Scholar 

  18. Frishman WH, Henderson LS, Lukas MA (2008) Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Vasc Health Risk Manag 4:1387–1400

    PubMed  CAS  Google Scholar 

  19. Wen H, Jiang H, Lu Z, He B, Hu X, Chen J, Zhao D (2009) Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. Tohoku J Exp Med 218:121–127

    Article  PubMed  CAS  Google Scholar 

  20. Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM (1997) Tissue factor antigen and activity in human coronary atherosclerotic plaques. Lancet 349:769–771

    Article  PubMed  CAS  Google Scholar 

  21. Carter AM (2005) Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2:113–121

    Article  PubMed  Google Scholar 

  22. Golino P, Ragni M, Cirillo P, Scognamiglio A, Ravera A, Buono C, Guarino A, Piro O, Lambiase C, Botticella F, Ezban M, Condorelli M, Chiariello M (2000) Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. Am J Physiol Heart Circ Physiol 278:H1507–H1516

    PubMed  CAS  Google Scholar 

  23. Erlich JH, Boyle EM, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N (2000) Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia–reperfusion injury by reducing inflammation. Am J Pathol 157:1849–1862

    Article  PubMed  CAS  Google Scholar 

  24. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R (2000) Angiotensin converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 86:139–143

    PubMed  CAS  Google Scholar 

  25. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Löffler BM, Ganten D, Schneider W, Haller H, Luft FC (2000) Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 36:282–290

    PubMed  CAS  Google Scholar 

  26. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R (2000) Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 86:139–143

    PubMed  CAS  Google Scholar 

  27. Koh KK, Chung WJ, Ahn JY, Han SH, Kang WC, Seo YH, Ahn TH, Choi IS, Shin EK (2004) Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 177:155–160

    Article  PubMed  CAS  Google Scholar 

  28. Li N, Zhu W, Chen L, Ke Y (2006) Effects of valsartan and captopril on expression and activity of rabbit vascular smooth muscle cell tissue factors and tissue factor pathway inhibitors. Chin J Cardiol 34:922

    CAS  Google Scholar 

  29. Soeda S, Tsunoda T, Kurokawa Y, Shimeno H (1998) Tumor necrosis factor-α induced release of plasminogen activator inhibitor-1 from human umbilical vein endothelial cells: involvement of intracellular ceramide signaling event. Biochim Biophys Acta 1448:37–45

    Article  PubMed  CAS  Google Scholar 

  30. Birgel M, Gottschling-Zeller H, Röhrig K, Hauner H (2000) Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 20:1682–1687

    Article  PubMed  CAS  Google Scholar 

  31. Rössig L, Haendeler J, Mallat Z, Hugel B, Freyssinet JM, Tedgui A, Dimmeler S, Zeiher AM (2000) Congestive heart failure induces endothelial cell apotosis: protective role of carvedilol. J Am Coll Cardiol 36:2081–2089

    Article  PubMed  Google Scholar 

  32. Polte T, Oberle S, Schder H (1997) Nitric oxide protects endothelial cells from tumor necrosis factor-α mediated cytotoxicity: possible involvement of cyclic GMP. FEBS Lett 409:46–48

    Article  PubMed  CAS  Google Scholar 

  33. Castro P, Vukasovic JL, Chiong M, Díaz-Araya G, Alcaino H, Copaja M, Valenzuela R, Greig D, Pérez O, Corbalan R, Lavandero S (2005) Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Eur J Heart Fail 7:1033–1039

    Article  PubMed  CAS  Google Scholar 

  34. Verma S (2004) Angiotensin receptor blockers and myocardial infarction. BMJ 329:1248–1249

    Article  PubMed  Google Scholar 

  35. Kveiborg B, Major-Petersen A, Christiansen B, Torp-Pedersen C (2007) Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol or Metroprolol European Trial. Vasc Health Risk Manag 3:31–37

    PubMed  CAS  Google Scholar 

  36. McDonald MA, Simpson SH, Ezedowits JA, Gyenes G, Tsuyuki RT (2005) Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ doi:10.1136/bmj.38595.518542.3A

  37. Wang J, Zhu TB, Yang ZJ, Wang LS, Ma WZ (2005) Study of free tissue factor pathway inhibitors in acute coronary syndrome. Nanjing Med Univ Trans Nat Sci Ed 25:259–261

    CAS  Google Scholar 

  38. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG (1998) Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart diseases patients. Thromb Haemost 79:495–499

    PubMed  CAS  Google Scholar 

  39. Wu Y, Sun B, Dai Q, Wang W (2006) Changes in plasma tissue factor and tissue factor pathway inhibitor levels in patients with acute myocardial infarction undergoing anticoagulant therapy. Chin J Med 41(6):35–36

    Google Scholar 

  40. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K (1999) Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 22:2908–2913

    Google Scholar 

Download references

Acknowledgment

This work was supported by research project of Heilongjiang Provincial Natural Science Foundation (D2007-74), funded by Heilongjiang Provincial Department of Education (11511152) and Heilongjiang Provincial Department of Health (2005235).

Author information

Authors and Affiliations

  1. No. 1 Department of Geriatrics, Fourth Affiliated Clinical Medical College, Harbin Medical University, No. 37, Yiyuan St, Nangang District, Harbin, 150001, Heilongjiang, China

    Junmin Yu & Zhenzhong Ge

  2. Department of Cardiology, First Affiliated Clinical Medical College, Harbin Medical University, Harbin, Heilongjiang, China

    Jiyi Zhao

  3. Central Laboratory of the Second Affiliated Clinical Medical College, Harbin Medical University, Harbin, Heilongjiang, China

    Wei Liu

  4. Department of Cardiology, Tongliao City Hospital, Inner Mongolia, 02800, China

    Yongli Du

Authors
  1. Junmin Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiyi Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhenzhong Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yongli Du
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junmin Yu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, J., Zhao, J., Liu, W. et al. Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. Heart Vessels 26, 646–653 (2011). https://doi.org/10.1007/s00380-010-0106-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-010-0106-0

Keywords

Search

Navigation